Correlationship between total proteins SUMOylation and papillary thyroid carcinoma in males

Abstract

Abstract:

ObjectiveTo investigate the relationship between protein SUMOylation level and the prognosis of papillary thyroid carcinoma(PTC) in males.MethodsProtein SUMOylation levels in PTC was analyzed by bioinformatics based on GTEx and TCGA databases and validated by immunohistochemical staining and Western blotting in our clinical pairs specimens. The mRNA expression of the protein SUMOylation associated genes were measured by fluorescent quantitative real-time polymerase chain reaction (qRT-PCR) in surgical pairs specimens.ResultsThe expression level of SUMOylation in the tumor tissues of PTC showed an elevated trend（P<0.05）, and was associated with poor prognosis of the patients by TCGA and GTEx databases analysis(P=0.021）. In the clinical samples of our hospital, it was verified that the level of SUMOylation in tumor tissues was higher than that of the paired non-tumor tissues（P<0.05）. However, qRT-PCR showed no significant changes in the transcriptional level of the protein SUMOylation associated genes in most cases.ConclusionsProtein SUMOylation in thyroid tumor tissues were higher than that in paired non-tumor tissues, and the higher SUMOylation levels levels in tumor tissues were, the shorter overall survival time of the patients was.

Key words:SUMOylation,Males,Papillary thyroid carcinoma (PTC)

CLC Number:

R736.1

WU Qiao, LIU Wei, ZHENG Jiaojiao, WANG Cong, AI Zhilong. Correlationship between total proteins SUMOylation and papillary thyroid carcinoma in males[J]. Journal of Surgery Concepts & Practice, 2024, 29(04): 336-344.

Figures/Tables7

Item	1	2	3	4	5	6
Age	27	36	56	42	30	41
The maximum focal diameter (cm)	0.7	1.1	1.2	0.8	2.0	1.5
Lymph node metastasis	Yes	Yes	Yes	No	Yes	Yes
Neoplasm staging	T1N1M0	T3N1M0	T1N1M0	T1N0M0	T1N1M0	T1N1M0

Tab 1

Fig 1

SUMO1 expresstion level	Female (n=76)	Male (n=24)	Total (n=100)
High	39 （51.32）	19 （79.17）	58 （58.00）
Medium	10 （13.16）	3 （12.50）	13 （13.00）
Low	27 （35.52）	2 （8.33）	29 （29.00）

Tab 2

Fig 2

Fig 3

Tab 3

Clinical information of 100 paired samples[$\overline{x}\pm s$/n(%)]

Item	Female	Male	Subtotal	Total	Rank sum test
No.	H (39)	H(19)	H(58)	100
	M(10)	M(3)	M(13)	F(76)
	L(27)	L(2)	L(29)	M(24)
The maximum focal diameter(cm)	H(1.79±1.50)	H(1.35±0.83)	H(1.76±1.47)	1.46±0.96	Hvs. M&L,P<0.01
	M(1.25±0.72)	M(1.07±0.48)	M(1.21±0.68)	F(1.51±1.16)
	L(1.19±0.64)	L(0.95±0.46)	L(1.19±0.75)	M(1.28±0.76)
The mean lesion No.	H(1.79±0.51)	H(1.74±0.50)	H(1.77±0.56)	1.75±0.96	ns
	M(2.00±1.00)	M(1.33±0.72)	M(1.84±0.83)	F(1.79±0.86)
	L(1.70±0.70)	L(1.00±0)	L(1.65±0.65)	M(1.63±0.46)
Membrane immersion	H(61.53%/24)	H(68.42%/13)	H(63.79%/37)	53.00%/53	Hvs. M&L，P=0.012
	M(50.00%/5)	M(33.33%/1)	M(46.15%/6)	F(51.32%/39)
	L(37.03%/10)	L(0)	L(34.48%/10)	M(58.33%/14)
Peripheral tissue invasion	H(28.20%/11)	H(15.79%/3)	H(24.14%/14)	19.00%/19	ns
	M(20.00%/2)	M(0)	M(15.38%/2)	F(21.05%/16)
	L(11.11%/3)	L(0)	L(10.34%/3)	M(12.50%/3)
Cevical lymph node metastasis	H(64.10%/25)	H(42.11%/8)	H(56.90%/33)	50.00%/50	ns
	M(30.00%/3)	M(33.33%/1)	M(30.77%/4)	F(53.95%/41)
	L(48.15%/13)	L(0)	L(44.83%/13)	M(37.50%/9)

Tab 3

Fig 4

References19

[1]	田文. 甲状腺癌诊治之中国经验与未来走向[J].临床外科杂志,2020,28(3):201-204.
	TIAN W. Chinese experience and future trends in the diagnosis and treatment of thyroid cancer[J].J Clin Surg,2020,28(3):201-204.
[2]	田文, 郗洪庆. 分化型甲状腺癌外科诊疗进展及展望[J].中国实用外科杂志,2020,40(1):78-82.
	TIAN W, XI H Q. Progress and prospects of surgical diagnosis and treatment of differentiated thyroid cancer[J].Chin J Pract Surg,2020,40(1):78-82.
[3]	LI M, DAL MASO L, VACCARELLA S. Global trends in thyroid cancer incidence and the impact of overdiagnosis[J].Lancet Diabetes Endocrinol,2020,8(6):468-470.
[4]	MAMMEN J S R, CAPPOLA A R. Autoimmune thyroid disease in women[J].JAMA,2021,325(23):2392-2393. doi:10.1001/jama.2020.22196pmid:33938930
[5]	LUNDGREN C I, HALL P, DICKMAN P W, et al. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study[J].Cancer,2006,106(3):524-531. doi:10.1002/cncr.21653pmid:16369995
[6]	HAN Z J, FENG Y H, GU B H, et al. The post-translational modification, SUMOylation, and cancer (Review)[J].Int J Oncol,2018,52(4):1081-1094.
[7]	BECARES N, GAGE M C, PINEDA-TORRA I. Posttranslational modifications of lipid-activated nuclear receptors: focus on metabolism[J].Endocrinology,2017,158(2):213-225. doi:10.1210/en.2016-1577pmid:27925773
[8]	SEELER J S, DEJEAN A. SUMO and the robustness of cancer[J].Nat Rev Cancer,2017,17(3):184-197.
[9]	CUI W, SUN M, ZHANG S, et al. A SUMO-acetyl switch in PXR biology[J].Biochim Biophys Acta,2016,1859(9):1170-1182. doi:S1874-9399(16)30030-Xpmid:26883953
[10]	DE CRISTOFARO T, MASCIA A, PAPPALARDO A, et al. Pax8 protein stability is controlled by sumoylation[J].J Mol Endocrinol,2009,42(1):35-46. doi:10.1677/JME-08-0100pmid:18974227
[11]	FLOTHO A, MELCHIOR F. Sumoylation: a regulatory protein modification in health and disease[J].Annu Rev Biochem,2013,82:357-385.
[12]	DAVIES L, WELCH H G. Current thyroid cancer trends in the United States[J].JAMA Otolaryngol Head Neck Surg,2014,140(4):317-322.
[13]	Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma[J].Cell,2014,159(3):676-690. doi:10.1016/j.cell.2014.09.050pmid:25417114
[14]	MONGELLI M N, GIRI S, PEIPERT B J, et al. Financial burden and quality of life among thyroid cancer survivors[J].Surgery,2020,167(3):631-637.
[15]	AL-QURAYSHI Z, FARAG M, SHAMA M A, et al. Total thyroidectomyversuslobectomy in small nodules suspicious for papillary thyroid cancer: cost-effectiveness analysis[J].Laryngoscope,2020,130(12):2922-2926.
[16]	DE ANDRADE J P, LORENZEN A W, WU V T, et al. Targeting the SUMO pathway as a novel treatment for anaplastic thyroid cancer[J].Oncotarget,2017,8(70):114801-114815.
[17]	KESSLER J D, KAHLE K T, SUN T, et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis[J].Science,2012,335(6066):348-353. doi:10.1126/science.1212728pmid:22157079
[18]	BIEDERSTÄDT A, HASSAN Z, SCHNEEWEIS C, et al. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype[J].Gut,2020,69(8):1472-1482. doi:10.1136/gutjnl-2018-317856pmid:32001555
[19]	GÂTEL P, PIECHACZYK M, BOSSIS G. Ubiquitin, SUMO, and Nedd8 as therapeutic targets in cancer[J].Adv Exp Med Biol,2020,1233:29-54.